Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acitazanolast
- Development stage
- Unknown
- Lead developer
- Wakamoto
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Acitazanolast is a small molecule mast cell stabilizer and leukotriene receptor antagonist developed by Wakamoto Pharmaceutical. It is an active metabolite of tazanolast. Formulated as a 0.1% ophthalmic solution, acitazanolast is approved and marketed in Japan for the treatment of allergic conjunctivitis. It exerts its anti-allergic and anti-inflammatory effects by stabilizing mast cells, preventing the influx of calcium ions required for degranulation, and inhibiting the release of chemical mediators such as histamine and leukotrienes.
- Brand names
- AlegenceZepelin
- Other names
- 3-(1H-tetrazol-5-yl)oxanilic acidacitazanolast hydrateazitanolastzepenolast
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)
Beyond the preview
Go deeper on acitazanolast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acitazanolast.